Updates are available Correction dated 2019-05-28

Article History

Received: 15 February 2019

Accepted: 16 April 2019

First Online: 6 May 2019

Change Date: 28 May 2019

Change Type: Correction

Change Details: After publication of the original article [1], the authors have notified us that an updated version of Figures 1, 2 and 3 should have been published. The incorrect and revised figures can be found below.

Ethics approval and consent to participate

: All participants provided written informed consent in accordance with the declaration of Helsinki and the study was approved by the Ethics committee of the capital region of Denmark (H-15019063) along with the Danish Medicines Agency (CIV-16-12-017964).

: Not Applicable

: CEC/SY/UL/VOB/PDK/ETP/OBP/HBWL report no conflicts of interest pertaining to this work. FMA has received personal fees and/or honoraria for lecturing from Teva, Eli Lilly and Novartis. FMA is principal investigator for a Novartis Phase IV trial and member of advisory boards for Eli Lilly and Novartis.MA is a consultant or scientific advisor for Allergan, Amgen, Alder, Eli Lilly, Novartis and Teva, principal investigator for Amgen 20120178 (Phase II), 20120295 (Phase II), 20130255 (Open label extension), 20120297 (Phase III), 20150308 (Phase II), ElectroCore GM-11 gamma-Core-R, TEVA TV48125-CNS- 30068 (Phase III), Novartis CAMG334A2301 (Phase III) and Alder PROMISE-2 (Phase III). MA has no ownership interest and does not hold stock in any pharmaceutical company. MA serves as associated editor of Cephalalgia and co-editor of the Journal of Headache and Pain.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.